COVID-19 Vaccine Global Intellectual Property Policy
https://policybase.cma.ca/link/policy14458

POLICY TYPE
Policy document

DATE
2021-10-22

TOPICS
Physician practice, compensation, forms

COVID-19 Vaccine Global Intellectual Property Policy

Policy position recommendation

1. The CMA recommends that governments of the nations participating in the global vaccine Cold Chain initiative, the WHO, the World Health Organization, the World Intellectual Property Organization (WIPO), and the World Trade Organization (WTO) establish

2. The CMA recommends that the nation of Canada support a temporary, multilateral, global waiver of intellectual property rights for COVID-19 vaccines, vaccines approved for use by the WHO’s Emergency Use Listing (EUL), and medicines essential in the treatment of COVID-19 under the TRIPS Waiver.

3. The CMA supports giving CMA members in all four regions of the world adequate access to COVID-19 vaccines and medicines essential in the treatment of COVID-19.

4. The CMA recommends that governments of the nations participating in the global vaccine cold chain initiative, the WHO, the World Health Organization, and the World Trade Organization (WTO) establish a temporary, multilateral, global waiver of intellectual property rights for COVID-19 vaccines, vaccines approved for use by the WHO’s Emergency Use Listing (EUL), and medicines essential in the treatment of COVID-19 under the TRIPS Waiver.

5. The CMA supports giving CMA members in all four regions of the world adequate access to COVID-19 vaccines and medicines essential in the treatment of COVID-19.

6. The CMA recommends that governments establish a temporary, multilateral, global waiver of intellectual property rights for COVID-19 vaccines, vaccines approved for use by the WHO’s Emergency Use Listing (EUL), and medicines essential in the treatment of COVID-19 under the TRIPS Waiver.

7. The CMA supports giving CMA members in all four regions of the world adequate access to COVID-19 vaccines and medicines essential in the treatment of COVID-19.

8. The CMA recommends that governments establish a temporary, multilateral, global waiver of intellectual property rights for COVID-19 vaccines, vaccines approved for use by the WHO’s Emergency Use Listing (EUL), and medicines essential in the treatment of COVID-19 under the TRIPS Waiver.